Cargando…
Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study
The treatment options are currently limited, and the oncological outcomes remain unclear, for patients with metastatic urothelial carcinoma (mUC) with or without third-line systemic therapy. We aimed to evaluate the oncological outcomes in real-world daily clinical practice after platinum-based chem...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496337/ https://www.ncbi.nlm.nih.gov/pubmed/36140344 http://dx.doi.org/10.3390/biomedicines10092243 |
_version_ | 1784794244028825600 |
---|---|
author | Yamada, Toyohiro Nakane, Keita Enomoto, Torai Tomioka, Masayuki Taniguchi, Tomoki Ishida, Takashi Ozawa, Kaori Takagi, Kimiaki Ito, Hiroki Takeuchi, Shinichi Kawase, Makoto Kawase, Kota Kato, Daiki Takai, Manabu Iinuma, Koji Yokoi, Shigeaki Nakano, Masahiro Koie, Takuya |
author_facet | Yamada, Toyohiro Nakane, Keita Enomoto, Torai Tomioka, Masayuki Taniguchi, Tomoki Ishida, Takashi Ozawa, Kaori Takagi, Kimiaki Ito, Hiroki Takeuchi, Shinichi Kawase, Makoto Kawase, Kota Kato, Daiki Takai, Manabu Iinuma, Koji Yokoi, Shigeaki Nakano, Masahiro Koie, Takuya |
author_sort | Yamada, Toyohiro |
collection | PubMed |
description | The treatment options are currently limited, and the oncological outcomes remain unclear, for patients with metastatic urothelial carcinoma (mUC) with or without third-line systemic therapy. We aimed to evaluate the oncological outcomes in real-world daily clinical practice after platinum-based chemotherapy followed by pembrolizumab for mUC. This retrospective, multicenter cohort study included patients with mUC who received second-line pembrolizumab in Japan. The patients were divided into the treatment group (those who received third-line treatment) and the BSC group (those who did not receive other treatments). The primary endpoint of this study was to evaluate the oncological outcomes. Of 126 patients enrolled in this study, 40 received third-line therapy. The median follow-up period was 8.0 months. The median overall survival (OS) times were nine months in the BSC group and 17 months in the treatment group (p < 0.001). The median progression-free survival (PFS) times were 4 months in the BSC group and 14 months in the treatment group (p < 0.001). In the multivariate analysis, performance status and liver metastasis were significantly associated with OS. Third-line therapy may have clinical potential advantages for improving the oncological outcomes in patients with mUC. |
format | Online Article Text |
id | pubmed-9496337 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94963372022-09-23 Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study Yamada, Toyohiro Nakane, Keita Enomoto, Torai Tomioka, Masayuki Taniguchi, Tomoki Ishida, Takashi Ozawa, Kaori Takagi, Kimiaki Ito, Hiroki Takeuchi, Shinichi Kawase, Makoto Kawase, Kota Kato, Daiki Takai, Manabu Iinuma, Koji Yokoi, Shigeaki Nakano, Masahiro Koie, Takuya Biomedicines Article The treatment options are currently limited, and the oncological outcomes remain unclear, for patients with metastatic urothelial carcinoma (mUC) with or without third-line systemic therapy. We aimed to evaluate the oncological outcomes in real-world daily clinical practice after platinum-based chemotherapy followed by pembrolizumab for mUC. This retrospective, multicenter cohort study included patients with mUC who received second-line pembrolizumab in Japan. The patients were divided into the treatment group (those who received third-line treatment) and the BSC group (those who did not receive other treatments). The primary endpoint of this study was to evaluate the oncological outcomes. Of 126 patients enrolled in this study, 40 received third-line therapy. The median follow-up period was 8.0 months. The median overall survival (OS) times were nine months in the BSC group and 17 months in the treatment group (p < 0.001). The median progression-free survival (PFS) times were 4 months in the BSC group and 14 months in the treatment group (p < 0.001). In the multivariate analysis, performance status and liver metastasis were significantly associated with OS. Third-line therapy may have clinical potential advantages for improving the oncological outcomes in patients with mUC. MDPI 2022-09-09 /pmc/articles/PMC9496337/ /pubmed/36140344 http://dx.doi.org/10.3390/biomedicines10092243 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yamada, Toyohiro Nakane, Keita Enomoto, Torai Tomioka, Masayuki Taniguchi, Tomoki Ishida, Takashi Ozawa, Kaori Takagi, Kimiaki Ito, Hiroki Takeuchi, Shinichi Kawase, Makoto Kawase, Kota Kato, Daiki Takai, Manabu Iinuma, Koji Yokoi, Shigeaki Nakano, Masahiro Koie, Takuya Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study |
title | Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study |
title_full | Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study |
title_fullStr | Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study |
title_full_unstemmed | Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study |
title_short | Oncological Outcomes in Patients with Metastatic Urothelial Carcinoma after Discontinuing Pembrolizumab as a Second-Line Treatment: A Retrospective Multicenter Real-World Cohort Study |
title_sort | oncological outcomes in patients with metastatic urothelial carcinoma after discontinuing pembrolizumab as a second-line treatment: a retrospective multicenter real-world cohort study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9496337/ https://www.ncbi.nlm.nih.gov/pubmed/36140344 http://dx.doi.org/10.3390/biomedicines10092243 |
work_keys_str_mv | AT yamadatoyohiro oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT nakanekeita oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT enomototorai oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT tomiokamasayuki oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT taniguchitomoki oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT ishidatakashi oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT ozawakaori oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT takagikimiaki oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT itohiroki oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT takeuchishinichi oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT kawasemakoto oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT kawasekota oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT katodaiki oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT takaimanabu oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT iinumakoji oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT yokoishigeaki oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT nakanomasahiro oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy AT koietakuya oncologicaloutcomesinpatientswithmetastaticurothelialcarcinomaafterdiscontinuingpembrolizumabasasecondlinetreatmentaretrospectivemulticenterrealworldcohortstudy |